Patent: 6,019,980
✉ Email this page to a colleague
Summary for Patent: 6,019,980
| Title: | Nucleic acid respiratory syncytial virus vaccines |
| Abstract: | Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample. |
| Inventor(s): | Li; Xiaomao (Thornhill, CA), Ewashysyn; Mary E. (Willowdale, CA), Klein; Michel H. (Willowdale, CA) |
| Assignee: | Connaught Laboratories Limited (Willowdale, CA) |
| Application Number: | 08/476,397 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,019,980
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2039-02-26 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2039-02-26 | |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2039-02-26 | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
